XFOR – x4 pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
3/27
08:15 am
xfor
Medium
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
3/26
10:27 am
xfor
Low
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
3/25
06:10 am
xfor
High
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/25
06:01 am
xfor
High
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/11
08:00 am
xfor
Low
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
3/25/2025
06:01 am
xfor
-13.5%
MISS
11/13/2024
06:07 am
xfor
-57.8%
MISS
8/8/2024
06:01 am
xfor
-6.9%
BEAT
5/7/2024
06:01 am
xfor
-7.6%
MISS
3/27
08:15 am
Reiterates
Buy
Buy
HC Wainwright
Medium
4.2%
3/26
10:27 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
1.1%
3/26
10:11 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
1.3%
2/7
08:28 am
Reiterates
Buy
Buy
HC Wainwright
Low
-0.3%
1/14
08:02 am
Reiterates
Buy
Buy
HC Wainwright
High
-17.1%
3/26
06:13 am
xfor
Medium
Form S-8 X4 Pharmaceuticals, Inc
3/26
06:01 am
xfor
Medium
Form 10-K X4 Pharmaceuticals, Inc For: Dec 31
3/25
07:51 am
xfor
High
Form 8-K X4 Pharmaceuticals, Inc For: Mar 25
3/24
04:43 pm
xfor
High
Form DEF 14A X4 Pharmaceuticals, Inc For: Mar 24
3/14
04:07 pm
xfor
Medium
Form PRE 14A X4 Pharmaceuticals, Inc For: Mar 14
Show more
Top News Gainers
3/18 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. 33.7%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
Top News Decliners
3/20 Form 8-K X4 Pharmaceuticals, Inc For: Mar 18 -29.5%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3